Monkeypox
31
8
11
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
6.5%
2 terminated out of 31 trials
86.7%
+0.1% vs benchmark
19%
6 trials in Phase 3/4
54%
7 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 13 completed trials
Clinical Trials (31)
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
Mpox Paediatric and Adolescent Clinical Study
New York City Observational Study of Mpox Immunity
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus Disease
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Understanding MPXV Viral Clearance, Transmission Dynamics, and Mpox Vaccine Effectiveness in West Africa : Guinea
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk
Ocular Complications of Mpox in the Democratic Republic Congo
Tecovirimat in Non-hospitalized Patients With Monkeypox
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses.
Tecovirimat for Treatment of Monkeypox Virus
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV